p16阳性N3期口咽鳞状细胞癌患者的吸烟与乳头状瘤病毒DNA
回顾性分析2003至2016年在本癌症中心治疗的29例p16阳性N3期口咽鳞状细胞癌患者,5年总生存率和无进展生存率分别为67.5%和59.1%。吸烟史超过10包年和缺乏人乳头瘤病毒DNA与更差的总生存和无进展生存相关,诱导化疗或根治性颈清扫未与不同治疗结局相关。
要点
- p16阳性N3期口咽鳞状细胞癌患者5年总生存率为67.5%,无进展生存率为59.1%。
- 吸烟史超过10包年与更差的总生存(P=0.02)和无进展生存(P=0.02)相关。
- 缺乏人乳头瘤病毒DNA与更差的总生存(P=0.03)和无进展生存(P=0.02)相关。
核心结论
- 本系列p16阳性N3期口咽鳞状细胞癌患者的5年总生存率为67.5%。
- 吸烟史和病毒DNA是与生存相关的预后因素。
研究设计与样本
- 回顾性分析2003年至2016年在本癌症中心治疗的p16阳性N3期口咽鳞状细胞癌患者数据,共纳入29例。
- 终点为总生存和无进展生存。
主要发现
- 5年总生存率为67.5%,5年无进展生存率为59.1%。
- 吸烟史超过10包年与更差的总生存(P=0.02)和无进展生存(P=0.02)相关。
- 缺乏人乳头瘤病毒DNA与更差的总生存(P=0.03)和无进展生存(P=0.02)相关。
- 诱导化疗或根治性颈清扫未与不同的治疗结局相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We investigated the survival of patients with a p16-positive N3 oropharyngeal squamous cell carcinoma (OPSCC) and the prognostic significance of patient, tumor, and treatment characteristics. METHODS: We retrospectively reviewed the data of patients treated at our Cancer Center for a p16-positive N3 OPSCC between 2003 and 2016. End points were overall survival (OS) and progression-free survival (PFS). RESULTS: A total of 29 patients were included. The 5-year OS and PFS were 67.5% and 59.1%, respectively. Smoking history above 10 pack-years and the absence of human papillomavirus DNA were associated with worse OS (P = .02 and P = .03, respectively) and PFS (P = .02 and P = .02, respectively). Induction chemotherapy or radical neck dissection were not associated with different treatment outcomes. CONCLUSION: Patients with an N3 p16-positive oropharyngeal cancer in our series had a 5-year OS rate of 67.5%. Smoking history and viral DNA were prognostic factors associated with survival.
引用
- Gorphe P, Chekkoury Idrissi Y, Tao Y, et al. Smoking and papillomavirus DNA in patients with p16-positive N3 oropharyngeal squamous cell carcinoma. Head Neck. 2018. PMID: 30552841. doi:10.1002/hed.25523
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。